Cargando…

SIRPγ-expressing cancer stem-like cells promote immune escape of lung cancer via Hippo signaling

Cancer stem-like cells (CSLCs) acquire enhanced immune checkpoint responses to evade immune cell killing and promote tumor progression. Here we showed that signal regulatory protein γ (SIRPγ) determined CSLC properties and immune evasiveness in a small population of lung adenocarcinoma (LUAD) cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Chuan, Jin, Guoxiang, Wu, Hong, Cui, Wei, Wang, Yu-Hui, Manne, Rajesh Kumar, Wang, Guihua, Zhang, Weina, Zhang, Xian, Han, Fei, Cai, Zhen, Pan, Bo-Syong, Hsu, Che-Chia, Liu, Yiqiang, Zhang, Anmei, Long, Jie, Zou, Hongbo, Wang, Shuang, Ma, Xiaodan, Duan, Jinling, Wang, Bin, Liu, Weihui, Lan, Haitao, Xiong, Qing, Xue, Gang, Chen, Zhongzhu, Xu, Zhigang, Furth, Mark E., Haigh Molina, Sarah, Lu, Yong, Xie, Dan, Bian, Xiu-Wu, Lin, Hui-Kuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8884909/
https://www.ncbi.nlm.nih.gov/pubmed/35229723
http://dx.doi.org/10.1172/JCI141797
Descripción
Sumario:Cancer stem-like cells (CSLCs) acquire enhanced immune checkpoint responses to evade immune cell killing and promote tumor progression. Here we showed that signal regulatory protein γ (SIRPγ) determined CSLC properties and immune evasiveness in a small population of lung adenocarcinoma (LUAD) cancer cells. A SIRPγ(hi) population displayed CSLC properties and transmitted the immune escape signal through sustaining CD47 expression in both SIRPγ(hi) and SIRPγ(lo/–) tumor cells. SIRPγ bridged MST1 and PP2A to facilitate MST1 dephosphorylation, resulting in Hippo/YAP activation and leading to cytokine release by CSLCs, which stimulated CD47 expression in LUAD cells and consequently inhibited tumor cell phagocytosis. SIRPγ promoted tumor growth and metastasis in vivo through YAP signaling. Notably, SIRPγ targeting with genetic SIRPγ knockdown or a SIRPγ-neutralizing antibody inhibited CSLC phenotypes and elicited phagocytosis that suppressed tumor growth in vivo. SIRPG was upregulated in human LUAD and its overexpression predicted poor survival outcome. Thus, SIRPγ(hi) cells serve as CSLCs and tumor immune checkpoint–initiating cells, propagating the immune escape signal to the entire cancer cell population. Our study identifies Hippo/YAP signaling as the first mechanism by which SIRPγ is engaged and reveals that targeting SIRPγ represents an immune- and CSLC-targeting strategy for lung cancer therapy.